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PERSPECTIVES IN CLINICAL NEPHROLOGY
Nutrition in end-stage renal disease
Despite substantial improvements in the science and technol-
ogy of renal replacement therapy (RRT), the morbidity and
mortality of patients with end-stage renal disease (ESRD) re-
mains excessively high [1—41. Among the many factors that
adversely affect patient outcome, protein-calorie malnutrition
plays a major role [5—8] and has been shown to be highly
associated with increased morbidity and mortality in the ESRD
patient population. In this review, we define the importance of
nutrition on the outcome of ESRD patients, and explore the
possible mechanisms that cause and/or promote poor nutritional
status in these patients. Because the factors are different for
patients at different stages of ESRD and for different treatment
modalities, these factors will be discussed separately for chronic
renal failure (CRF) patients prior to initiation of RRT, patients
on chronic hemodialysis (CHD) and peritoneal dialysis (PD) and
finally, patients with an allograft. Measures to prevent malnutri-
tion, as well as several treatment options in ESRD patients who
are already malnourished will also be discussed.
When addressing this subject, it is also important to keep in
mind the debate about whether malnutrition is a simple reflection
of multiple co-morbidities in these patient populations or is an
independent risk that may aggravate existing co-morbidities.
While there is no definitive answer to this debate, recent studies
have suggested that the treatment of malnutrition per se improves
the risk of death in patients with renal failure and argues for the
consideration of malnutrition as another co-morbidity, albeit one
that strongly correlates with morbidity and mortality.
Indices of nutritional status
Before discussing the extent and importance of malnutrition, it
is important to discuss the indices of nutritional status in different
patient populations. Relatively simple biochemical measures such
as serum albumin, cholesterol, and creatinine [9], as well as more
complex and not readily available parameters such as plasma and
muscle amino acid profiles [101, prealbumin [11], and insulin-like
growth factor-i (IGF-i) [12] have been proposed as such indices.
In addition, analysis of body composition with different tech-
niques, such as anthropometric [13], bioelectrical impedance
analysis (BIA) [14—161, dual energy X-ray absorptiometry
(DEXA) [17, 18], and total body nitrogen (TBN) [19, 20] mea-
surements have also been advocated. A list of these indices with
their relationship to malnutrition is depicted in Table 1.
Among the parameters noted above, serum albumin is probably
the most extensively examined nutritional index in almost all
patient populations, probably due to its easy availability and
strong association with outcome [21, 22] especially in ESRD
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patients (vide infra). In fact, low serum albumin concentrations
are usually accompanied by other markers of malnutrition in
multiple studies with different patient populations including
ESRD patients [9, 13, 23, 24]. These observations have led to the
general concept that an abnormal serum albumin concentration
by itself is usually sufficient to diagnose protein-energy malnutri-
tion in ESRD patients. However, it should be kept in mind that
serum albumin concentration may also be affected by many other
co-existing problems in addition to malnutrition. Conditions that
promote an acute-phase response, such as infection and/or
trauma, can induce prompt and significant decreases in serum
albumin concentrations [25]. In this context, the decrease in
serum albumin concentrations often reflects the degree of illness
and inflammation, rather than the overall nutritional status [26,
271. A similar finding in CHD patients is suggested in a recent
study by Kaysen and colleagues [28] who reported that hypoalbu-
minemia in CHD patients may also reflect non-nutritional factors,
such as external losses and decreased synthesis.
The utilization of serum albumin as a nutritional index is
further complicated when one considers "the reverse of the coin,"
that is, the changes in serum albumin concentrations resulting
from protein-energy malnutrition. Since albumin has a half-life of
approximately 20 days and its serum concentrations are adjusted
by intra and extravascular fluid shifts [29], as well as compensatory
changes in synthesis and catabolism [30], its response as a visceral
protein to insidious malnutrition is rather late in the course of the
disease and to a variable extent [31]. Therefore, to the extent that
serum albumin reflects malnutrition, it should be considered as a
late index of nutritional status changes.
Several other serum proteins are being identified as additional
indices of malnutrition in addition to serum albumin alone. Serum
transferrin concentration, which is readily measured is a good and
relatively early indicator of visceral serum protein concentrations.
Serum concentrations below 200 mg/dl have been suggested as an
indicator of poor nutrition [32], hut it should be noted that these
concentrations may also be influenced by concomitant erythropoi-
etin and iron therapy. Prealbumin, another serum protein with a
half-life of two days, has been proposed as an index of nutritional
status [ii, 31]. Its serum concentration is closely associated with
the level of kidney function and therefore, while it is not partic-
ularly useful in patients with progressive CRF, it is probably most
useful in chronic dialysis patients with stable, albeit markedly
reduced renal function [33, 341. For the same reason, the lower
threshold of prealbumin that is associated with nutritional deple-
tion has not been identified in ESRD patients. Nevertheless, an
apparent decline in both transferrin and/or prealbumin concen-
trations should suggest inadequate nutrient intake. Finally, serum
IGF-1 has been proposed as another index of nutritional status
[23, 32, 35]. Since serum IGF-1 concentration is significantly
influenced by dietary protein and energy intake [36], it is reason-
able to expect relatively rapid changes in serum IGF-1 concentra-
tions with changes in nutrient intake [37]. As is the case for serum
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Table 1. Indices of malnutrition in end-stage renal disease patients
(1) Biochemical parameters
-Serum albumin concentrations < 4.0 g/dl
-Serum transferrin concentrations < 200 mg/dl
-Serum IGF-1 concentrations < 200 ng/ml
-Serum prealbumin concentrations < 30 mg/dl or an apparent
decreasing trend
-Abnormally low plasma and muscle essential amino acid
concentrations
-Low serum creatinine concentrations with other signs of uremia or
low creatinine kinetics
(2) Anthropometric measures
-Continuous decline in body weight or low % ideal body weight
(< 85%)
-Abnormal skinfold thickness, midarm muscle circumference and/or
muscle strength
(3) Body composition analysis
-Abnormally low % of lean body mass by bioelectrical impedance
analysis and/or DEXA
-Low total body nitrogen and/or nitrogen index (observed
nitrogen/predicted nitrogen)
(4) Dietary assessment
-Low spontaneous dietary protein intake by 24-hr urea nitrogen
excretion in chronic renal failure patients (< 0.7 g/kg/day) and
by protein catabolic rate in chronic dialysis patients (< 1.0 g/kg/
day)
prealbumin, the concentration of IGF-1 at which malnutrition is
significant is not established. Our current experience is that serum
IGF-1 concentrations below 200 ng/ml is usually associated with
other signs of poor nutrition [32, 38, 1• In addition, recent data
from our laboratory have suggested that longitudinal changes in
serum IGF-1 concentrations can prospectively predict the changes
in other nutritional parameters, specifically serum albumin con-
centrations in CHD patients [391.
In addition to serum protein concentrations, analysis of body
composition is another important tool for assessment of nutri-
tional status in ESRD patients. The simplest, but unfortunately
the least reliable technique is anthropometric studies. This rela-
tively easy but largely subjective test is a readily available method
that may be tried as a confirmatory analysis in any patient with
suspected protein-energy malnutrition. However, there are more
reliable and accurate methods of body composition analysis, such
as prompt neutron activation analysis (PNAA) which measures
TBN content and DEXA which is also reported to be useful in
ESRD patients [20, 40, 411. These measurements require expen-
sive equipment and are only available in small centers and their
validity need to be confirmed with further studies. A new prom-
ising method of nutritional assessment is BIA which has been
proposed as an accurate and reproducible measure of body
composition in various patient populations including ESRD pa-
tients [14, 42, 31. Although this method provides a good corre-
lation of total body water in normal subjects, the variance in
ESRD patients may be large. This is partly because BIA does not
detect acute changes in body water and does not take into account
the presence of peritoneal dialysis fluid. Therefore, for consis-
tency and accuracy, it is suggested that the measurements be done
pre-dialysis or 30 minutes post-dialysis in HD patients and without
the dialysate in PD patients [31• Several other issues that have
not been clarified are the validity of the results in moderately or
severely malnourished ESRD patients and its usefulness in pro-
spective studies. Finally, body composition can also be estimated
by creatinine kinetics, which correlates well with other lean body
mass measurements [44].
Estimation of dietary protein intake (DPI) by different methods
can also be used as a marker of overall nutritional status in the
stable ESRD patient. Although dietary recall is a direct and
simple measure of DPI, several studies have shown that this
method lacks accuracy in estimating the actual intake of patients,
even in experimental settings [45]. Therefore, other means of
measuring DPI, such as 24-hour urine urea nitrogen excretion in
chronic renal failure patients [46] or protein catabolic rate (PCR)
calculations in dialysis patients, have been suggested as useful
methods to estimate protein intake [471. However, it should be
noted that these indirect estimations of DPI are valid only in
stable patients, and may easily overestimate the actual intake in
catabolic patients where endogenous protein breakdown may lead
to a high urea nitrogen appearance [48J. More recently, there has
been an active debate whether PCR is mathematically linked to
Kt/V or is an independent nutritional parameter. The lack of
correlation between PCR and other nutritional markers such as
serum albumin suggests that the former is likely [45]. Therefore,
these indirect estimations of DPI and nutritional status should be
evaluated with caution.
In light of the above observations, it should be evident that an
assessment of malnutrition should rely on multiple indices of
nutritional status simultaneously. These indices should comprise
several biochemical measures, certainly including serum albumin
as well as an analysis of body composition if available. Multiple
markers used in this manner can therefore simultaneously reflect
both somatic tissue status from body composition analysis and
visceral protein status from serum proteins.
Extent of malnutrition in ESRD patients
Virtually every study which has evaluated the nutritional status
of ESRD patients has reported some degree of malnutrition in
this population. The prevalence of malnutrition has been esti-
mated to range from approximately 20 to 50% in different ESRD
patient populations using the above mentioned parameters.
Pre-dialysis patients
The prevalence of malnutrition is not limited to a specific stage
of ES RD. In fact, there is evidence to suggest that malnutrition is
prevalent even before initiation of RRT. In this context, an earlier
report from the feasibility phase of the Modification of Diet in
Renal Disease (MDRD) study (similar to the full MDRD study
but smaller in scope, without blood pressure randomization and
carried out for only one year) suggested that early signs of
malnutrition such as reductions in % desirable body weight (wt),
body mass index, anthropometric measurements and a notable
decline in urinary creatinine excretion were observed in chronic
renal failure patients as their renal function worsened [49j. There
were also large reductions in several plasma essential and total
amino acid concentrations in the patients with advanced renal
failure [50]. Similar observations were later reported, in abstract
form, based on the 1687 patients who were evaluated for partic-
ipation in the full scale MDRD study [51]. Of note, these
observations were made before the patients were randomized to
any of the dietary interventions of the study. We have recently
reported a prospective analysis of the effects of progression of
renal disease on CRF patients without dietary intervention fol-
lowed in our out-patient clinic [52] and were able to show that
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several indices of nutrition, such as DPI, serum transferrin, serum
cholesterol, serum IGF-1, percent body wt, and urinary creatinine
excretion decreased as renal function deteriorated.
Dialysis dependent patients
Hemodialysis. Once CRF patients are initiated on dialysis, the
extent of malnutrition becomes more evident [9, 53, 54]. Lowrie
and Lew reported serum albumin concentrations less than 3.7 g/dl
in 25% of their patient population which included more than
12,000 HD patients [71. Similar findings with regard to serum
albumin are found in a recent report by the Health Care
Financing Administration [55]. In an analysis of all Networks in
the United States, 53% of the chronic hemodialysis patients are
reported to have a serum albumin concentration between 3.5 and
3.9 g/dl and 22% of the patients had a serum albumin concentra-
tion of 3.4 g/dI and below. An analysis of the National Cooperative
Dialysis Study (NCDS) patient population revealed insufficient
dietary protein and energy intake in a notable proportion of
patients (approximately 23%), as well as reductions in body fat
and muscle stores in up to 40% of the study population [45]. Of
note, serum albumin concentrations were within normal ranges in
this patient population. Several smaller studies have shown evi-
dence of malnutrition ranging between 45 to 60% of their patient
populations using either a single or combined indices of malnu-
trition [10, 12, 56, 57].
Analysis of body composition with different techniques has also
shown evidence of malnutrition in CHD patients [18, 42]. in fact,
Rayner et a! reported that body protein depletion was detected in
up to 26% of their patients who were considered to be nutrition-
ally normal by other indices of nutrition [40]. Another recent
report by Pollock et al [41] suggested that 76% of their chronic
dialysis patient population had a nitrogen index lower than the
predicted value (observed nitrogen/predicted normal nitrogen)
when analyzed with PNAA that measures TBN.
Peritoneal dialysis patients. Malnutrition appears to be even
more prevalent in CAPD patients. A recent multicenter interna-
tional study reported severe to moderate malnutrition in 40% of
the CAPD patients as evaluated by subjective nutritional assess-
ment [58]. Several studies have confirmed the high prevalence of
poor nutritional status in this patient population [57, 59, 60]. Most
recently, Cianciaruso et al reported the extent of malnutrition in
CAPD patients (42.3%) to be higher than their CHD population
(30.8%) [611.
Transplant patients
The information on the extent of malnutrition in transplant
patients is more limited. In a study of 6 transplant patients,
Williams et al reported whole-body content of nitrogen, potas-
sium, and calcium to be significantly less than normal values,
especially during the first year of transplantation [62]. Miller et a!
suggested that although several indices of nutrition improve after
transplantation, abnormalities in anthropometric measurements
can be found in up to 38% of transplant patients [63]. Similarly,
Horber et al found evidence of myopathy and decreased muscle
function in 12 otherwise clinically stable renal transplant patients
[64]. Most recently, Qureshi et al reported that transplant patients
had some degree of depletion of visceral protein stores suggested
by decreased serum albumin concentrations specifically within the
first year of transplantation [65]. However, these authors did not
see this decrease in a group of patients who were, on average,
seven years post-transplant. Nevertheless, the actual prevalence of
malnutrition, especially in patients with recurrent acute graft
failure remains to be identified, and studies in this patient
population should be encouraged.
Effect of malnutrition on morbidity and mortality
A number of studies have documented the increased mortality
and morbidity in ESRD patients suffering from malnutrition [8,
32]. This direct relationship between poor nutrition and outcome
is also observed in patient populations other than ESRD, partic-
ularly in acutely ill and elderly patients [24, 26, 64]. A recent study
by Herrmann and colleagues [22] of more than 15,000 hospital-
ized patients suggested that serum albumin concentrations on
admission strongly predicted death, length of stay and readmis-
sion. Specifically, patients with serum albumin less than 3.4 g/dl on
admission had 10% higher in-hospital mortality as compared to
patients with serum albumin higher than 3.5 g/dl.
It is interesting to note that in the ESRD patient, malnutrition
is rarely documented as a cause of death. Nevertheless, there is a
body of evidence to suggest that the nutritional status of ESRD
patients plays a major role in the outcome of these patients. In
fact, the first apparent indication of suboptimal nutrition and
related poor outcome in ESRD patients came from the analysis of
the NCDS results. In this well-known comprehensive study of 262
CHD patients divided into four groups, the patient group with the
lowest PCR, which presumably reflects the DPI in stable CHD
patients, had the highest treatment failure and drop-out rate [5].
In addition, this group of patients had the highest death rate
following the termination of the study. This observation was later
confirmed in a study by Acchiardo et al who suggested that CHD
patients with a PCR below 0.63 g/kg/day had a higher mortality
and hospitalization rate compared to patients with PCR above
0.93 g/kg/day [66].
The most comprehensive study on this issue was reported by
Lowrie and Lew [7]. In their cross-sectional analysis of more than
12,000 CHD patients, they identified serum albumin concentra-
tion as the most powerful indicator of mortality. The risk of death
in patients with serum albumin concentration below 2.5 g/dl was
close to 20-fold compared to patients with serum albumin of 4.0 to
4.5 g/dl, which is considered to be the reference range. More
importantly, when compared to this reference range, even serum
albumin values of 3.5 to 4.0 g/dl resulted in a twofold increase in
the relative risk of death. It is important to note that this latter
value of albumin is in the range of "normal" for many laborato-
ries. Therefore, a small difference in serum albumin concentra-
tions, even when it is in "normal" range, may adversely affect the
relative mortality risk in CHD patients. In addition to serum
albumin, Lowrie and Lew were able to define a close relationship
between mortality and other biochemical markers of nutrition.
Specifically, low blood urea nitrogen (BUN) and serum choles-
terol concentrations, indicators of low protein and energy intake,
as well as low serum creatinine, an indicator of decreased muscle
mass, were also associated with increased risk of death in this
patient population. In a recent report, they also included anion
gap and percent of ideal body wts of these patients as other
significant predictors of death and suggested that four out of the
six most significant predictors of death in CHD patients, namely
serum creatinine, albumin, anion gap, and percent ideal body wt,
were nutritional factors [671. These observations by Lowrie and
Lew were later confirmed by many other studies in multiple
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patient populations and have highlighted the association of serum
albumin with morbidity and mortality [6, 68—70].
Several nutritional parameters other than serum albumin have
also been associated with increased risk of death, including serum
transferrin, prealbumin, and IGF-1, as well as total lymphocyte
counts, and abnormal plasma amino acid profiles [7, 24, 34, 71,
72]. However, most of these studies were performed on smaller
study populations and their validity, or relationship to serum
albumin, remains to be determined.
Similar observations can be made in CAPD patients. Teehan et
al, as well as Blake et al and Rocco et al, reported that serum
albumin was the best predictor of death and a strong predictor of
hospitalization days [73—75]. Most recently, Lowrie, Huang, and
Lew reported their findings for death risk predictors among 1,522
peritoneal dialysis patients [76]. In this regard, it is important to
note that the relative risk of death for patients with low serum
albumin was the same for CHD and PD patients, suggesting that
peritoneal losses of albumin does not mitigate against serum
albumin as a prognostic factor of mortality. Finally, Avram et al
also reported the independent association of serum albumin,
prealbumin and creatinine with increased risk of death in their
patient population who were followed up to seven years [77].
There is also good evidence to suggest that the pre-dialysis
nutritional status of ESRD patients affects the outcome of these
patients following the initiation of RRT [78]. In fact, analysis of
the United States Renal Data System (USRDS) data of patients
initiating dialysis have suggested that low serum albumin and
creatinine concentrations at the initiation of dialysis were associ-
ated with increased risk of death during the course of RRT [47,
77]. Similar findings were observed with serum creatinine concen-
trations. Comparable observations were made by Lowrie and
colleagues, based on a large number of patients starting dialysis
[47]. Thus, a serum albumin less than 4.0 g/dl, along with other
indicators of inadequate nutritional status, such as weight loss,
decreased transferrin, decreased cholesterol and decreased mus-
cle mass (as indicated by serum creatinine inappropriately low for
the level of renal function) at initiation of dialysis correlate with
subsequent poor outcome during the course of RRT,
Very limited information is available with regard to the associ-
ation of nutritional status of transplant patients and mortality and
morbidity. As stated previously, transplant patients appear to have
decreased serum albumin concentrations and lean body mass,
especially during the early years of transplantation. However,
there are no published studies, at least to our knowledge, that
evaluates the relationship of malnutrition to allograft or patient
outcome.
Factors affecting the nutritional status of ESRD patients
Considering the magnitude of the problem, one can anticipate
that multiple factors play important roles in the evolution of
malnutrition in ESRD patients. Many of these factors act simul-
taneously in the progression from suboptimal nutrition to appar-
ent malnutrition. We shall discuss these factors with reference to
the different stages ESRD. However, it is important to note that
most of these factors overlap between the various stages and
therapies of renal disease and whereas some of these may resolve
with appropriate measures, others may persist through all stages
of ESRD.
Pre -dialysis patients
One of the most significant indicators of advanced uremia is an
apparent decrease in appetite [79]. Although not studied in detail,
it has been generally thought that anorexia worsens as renal
failure progresses. Several recent studies, both cross-sectional and
prospective in design, have addressed this issue and appropriately
emphasized the adverse effects of decreased food intake on
nutritional status.
In an early cross-sectional study of 900 CRF patients by Hakim
and Lazarus, it was noted that CRF patients tended to decrease
their spontaneous food intake with decreasing renal function, as
documented by decreasing urea to creatinine ratio as renal
function decreased [80]. The authors also noted that this decrease
in food intake was spontaneous and not because of dietary
counselling, and was specifically related to decreased intake of
high protein products such as meat.
The results from the feasibility phase as well as the full scale
MDRD study also provided important observations on this issue
suggesting a positive correlation between the true glomerular
filtration rate (GFR) and the actual and reported protein and
calorie intake [49, 51]. Thus, at entry into the study (that is, before
assignment to different dietary groups), it was found that the
lower the GFR, the lower was the protein and energy intake. The
authors suggested that the signs of protein and calorie malnutri-
tion became overt when the GFR was less than 10 mI/mm.
It should be noted that the above mentioned studies were all
cross-sectional in design. More recently, a prospective analysis of
protein intake by patients with progressive renal disease, but with
minimal dietary interventions, has been published [52]. The
dietary protein intake (DPI) of more than 90 patients was
calculated by sequential collections of 24-hour urine collections
and evaluated for urine urea nitrogen excretion, which reflects
DPI in stable patients. The results indicated that many patients
spontaneously restricted their DPI with progression of renal
disease, with DPI less than 0.6 glkglday when CrCl was less than
10 mI/mm. Importantly, other markers of nutrition such as weight
and IGF-1 concentrations correlated with renal function as well as
dietary protein intake.
Although a cause and effect relationship cannot be readily
defined, these findings suggest that a relationship exists between
extent of renal failure, spontaneous dietary protein and energy
intake, and nutritional status. Indeed, a recent report by Berg-
strom and colleagues, in abstract form, suggested that accumula-
tion of a low (<5 kDa) molecular weight substance, isolated from
uremic plasma ultrafiltrate and normal urine, may be a potential
marker of this decreased food intake in uremia, since it induces a
dose-dependent suppression of appetite after injection to other-
wise normal rats [81].
These observations clearly do not apply to patients who may be
prescribed, under close observations, protein restricted diets
supplemented with essential amino acids and/or their keto-ana-
logs. Several studies, including the MDRD study, have shown that
with close supervision and a heavy emphasis on calorie intake,
patients may have protein restricted diets without the develop-
ment of overt malnutrition [82—84]. While the clinical efficacy of
such interventions and their cost has been questioned recently [47,
851, such interventions could not be easily applied to the majority
of patients with renal failure; thus, in the majority of patients who
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are not on a closely supervised diet, the development of progres-
sive renal failure is accompanied pan passu with the development
of malnutrition.
The decreased spontaneous DPI is, of course, only one of the
factors that contributes to the development of malnutrition in
pre-dialysis renal failure patients. Several other metabolic abnor-
malities, related to the loss of renal tissue as well as renal function,
become apparent in these patients. Metabolic acidosis, which
commonly accompanies progressive renal failure, also promotes
malnutrition, by increased protein catabolism [86, 87]. Studies by
Mitch et at suggested that muscle proteolysis is stimulated by an
ATP-dependent pathway involving ubiquitin and proteasomes
during metabolic acidosis [88]. More recently, Balimer et at
reported that metabolic acidosis of seven days duration, induced
with high doses of NH4C1 (4.2 mmol/kg) significantly reduced
albumin synthesis and induced negative nitrogen balance in
otherwise healthy subjects [89]. In spite of these experimental
data, the clinical relevance of correcting metabolic acidosis in
ESRD patients is still not defined and there are as yet no
prospective long-term studies that have revealed the effects of
correction of metabolic acidosis on nutritional status in ESRD
patients.
A relevant issue that needs mentioning is that in CRF patients
total bicarbonate concentrations generally decrease as renal func-
tion worsens [52]. Since DPI is actually estimated by measuring
urinary urea nitrogen excretion in stable patients, considering the
catabolic effects of metabolic acidosis [46], the calculated DPI
may actually be overestimated in patients with advanced renal
failure when metabolic acidosis is most apparent.
Several hormonal derangements including insulin resistance,
increased glucagon concentrations, and secondary hyperparathy-
roidism are also implicated as factors in the development of
malnutrition in chronic renal failure [87, 90]. A post-receptor
defect in insulin responsiveness of tissues is the most likely cause
of insulin resistance and associated glucose intolerance in uremia
[91]. However, it is not clear to what extent this insulin resistance
affects protein metabolism in CRF. It has also been suggested that
hyperparathyroidism usually seen in chronic renal failure is, at
least in part, responsible for this decreased tissue responsiveness
to insulin via inhibition of insulin secretion by pancreatic a-cells
[90, 92]. Increased concentrations of parathyroid hormone have
also been implicated as a catabolic factor that promotes protein
metabolism in uremia by enhancing amino acid release from
muscle tissue [93]. Finally, there are several abnormalities in
thyroid hormone profiles of uremic patients, characterized by low
thyroxine and triiodothyronine concentrations [94]. These
changes resemble the changes seen in prolonged malnutrition in
other patient populations [951 and it has been suggested that the
thyroid hormone profile of malnutrition [96] and renal failure is a
maladaptative response to decreased energy intake and an effort
to preserve overall energy balance.
More recently, abnormalities in growth hormone and IGF-1
axis have been suggested as an important factor in the develop-
ment of malnutrition in CRF [97]. Growth hormone is the major
promoter of growth in children and exerts several anabolic actions
in adults, such as enhancement of protein synthesis, increased fat
mobilization and increased gluconeogenesis, with IGF-1 as the
major mediator of these actions [98—1001. Although several
studies have shown that plasma concentrations of growth hor-
mone actually increase during the progression of renal failure,
probably due to its reduced renal clearance, recent evidence
suggests that uremia per se is associated with the development of
resistance to growth hormone actions at cellular levels [101]. This
subject is reviewed in detail in a recent editorial by Krieg, Santos
and Chan [97]. In this context, studies by Chan et a! and Tonshoff
et al have elegantly shown that in experimental settings, uremia is
characterized by reduced hepatic growth hormone receptor
mRNA as well as hepatic IGF-1 mRNA expression [102, 103].
This blunted response would be expected to attenuate the ana-
bolic actions of these hormones. Interestingly, these abnormalities
can also be observed with decreased food intake, as well as in
experimental metabolic acidosis [104]. Clinically, metabolic aci-
dosis and decreased dietary protein and energy intake are also
associated with decreased IGF-1 [36, 89], although it is not clear
which is the primary response and which is the secondary effect
[37]. Thus, the current evidence suggest an interesting, as yet not
well defined interrelationship between these hormonal, metabolic,
and nutritional factors which are involved in the evolution of
malnutrition in ESRD patients.
Specific co-morbid conditions can also facilitate the develop-
ment of malnutrition in chronic renal failure patients. Patients
with CRF secondary to diabetes mellitus, which is the leading
cause of ESRD in United States, have a higher incidence of
malnutrition as compared to patients who are not diabetic. The
etiology of this observation is probably multifactorial. Diabetic
patients are likely to be more prone to malnutrition because of
associated gastrointestinal symptoms such as gastroparesis, nau-
sea and vomiting, bacterial overgrowth in the gut, pancreatic
insufficiency, as well as high occurrence of nephrotic syndrome
and related complications [321.
Depression, which is commonly seen in ESRD patients is also
associated with anorexia. In addition, chronic renal failure pa-
tients are usually prescribed a large number of medications,
particularly sedatives, phosphate binders, and iron supplements,
which are also associated with gastrointestinal complications.
Finally, the socioeconomic status of the patients, their lack of
mobility, as well as their age, are other predisposing factors in the
development of malnutrition in ESRD patients.
It is therefore conceivable that the progressive anorexia seen in
chronic renal failure, as well as the non-nutritional factors related
to uremia, such as metabolic acidosis, hormonal derangements,
and co-morbid conditions, provide additive factors for develop-
ment of insidious malnutrition in pre-dialysis patients.
Maintenance dialysis patients
As stated above, many of the factors that predispose the
pre-dialysis patient to malnutrition actually continue during the
course of maintenance dialysis therapy regardless of the modality
utilized. We will therefore discuss those factors with specific
emphasis of issues directly related to the mode of dialytic therapy.
Increased requirements of protein and energy in dialysis patients
In general, the "minimal" daily protein requirement is one that
maintains a neutral nitrogen balance and prevents malnutrition;
this has been estimated to be a daily protein intake of approxi-
mately 0.6 glkg in healthy individuals, with a "safe level" of
protein intake equivalent to the minimal requirement plus 2
"SDs", or approximately 0.75 g/kg/day [105, 106]. This suggested
intake of protein for normal individuals does not necessarily apply
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to ESRD patients who may require higher levels due to concur-
rent abnormalities. Indeed, Borah et al have shown that for
hemodialysis patients a protein intake of 1.4 glkglday is needed to
maintain a positive or neutral nitrogen balance during non-
dialysis days and even this intake may not be adequate for dialysis
days [107]. There are very few other studies that have systemati-
cally evaluated the actual protein requirements of dialysis pa-
tients. Nevertheless, a minimum of 1.2 g/kg/day is suggested as
safe level of dietary protein intake for CHD and PD patients,
based on several metabolic balance studies [108]. These suggested
levels of DPI are clearly much higher (almost twofold) than the
normal population and there are a number of identified factors
that actually increase the requirement of protein intake in dialysis
patients.
Inappropriately high resting energy expenditure (REE) is an-
other proposed mechanism for the increased requirements of
protein and energy in hemodialysis patients. Several earlier
studies on this issue reported that REE was not different between
normal healthy controls and chronic renal failure patients both
prior to and after initiation of RRT [109—111]. However, these
studies were subject to several limitations, particularly in the
methodology used for measuring energy expenditure, namely the
metabolic cart. Ikizler and Hakim, using the more precise whole-
room indirect calorimeter, have recently reported that REE is
actually higher in CHD patients, even on non-dialysis days,
compared to age, sex, and body mass index matched normal
controls [112]. Interestingly, this higher level of REE was further
increased during the hemodialysis procedure when the nutrient
losses and catabolism are at maximum. This increase in REE
during non-dialysis periods and hemodialysis comprise an addi-
tional increase of 8 to 16% of REE compared to normal individ-
uals. Several other preliminary reports have also shown results
consistent with these observations, especially after adjusting REE
for fat free mass, where the majority of energy expenditure occurs
[113, 114]. Although the cause of this increased REE in CHD
patients is not well-defined, it is clearly another component of the
propensity of these patients to develop malnutrition.
Factors related to hemodialysis
Hemodialysis has long been considered a catabolic process and
inevitable losses of nutrients during HD is an important compo-
nent of dialysis related catabolism. Earlier studies by Kopple et al
and Wolfson et al have documented a loss of 5 to 8 g of free amino
acids during each hemodialysis session, using low-flux dialyzers
[115, 1161. With the use of larger pore size membranes, the
so-called high-flux membranes, these losses further increase by
30% compared to low-flux membranes, due to the larger surface
area of the membranes and higher blood flows used [117].
Simultaneous changes in plasma amino acid concentrations sug-
gested that these patients catabolized approximately 25 to 30 g of
body protein to compensate for these losses. More interestingly,
several studies have documented significant amounts of protein
and albumin losses across some high-flux membranes reused with
bleach and formaldehyde [117, 118], although these losses are
trivial until the 15th reuse. This continuous unavoidable loss of
nutrients repetitively predisposes the HD patient to negative
nitrogen balance, especially in the presence of inadequate intake.
Another well-defined, at least experimentally, cause of inappro-
priate protein catabolism in dialysis patients is the contact be-
tween blood and foreign material during hemodialysis, that is, the
effects of bioincompatibility [119]. It is now well-established that
the type of dialysis membrane used affects the protein metabolism
in CHD patients. In studies by Gutierrez et al, as well as Ikizler
and Hakim, bioincompatible membranes which vigorously acti-
vate the complement system also induce net protein catabolism as
compared to dialysis membranes which do not activate this
inflammatory response [117, 120]. Although both membranes
induce net protein catabolism, due to amino acid losses observed
during hemodialysis, this catabolism is more intense with bioin-
compatible membranes [117] and can be observed even at six
hours after initiation of dialysis in normal subjects [121]. Using
leucine turnover studies, Lim et al were unable to show any
adverse effects of dialysis with bioincompatible membranes on
protein metabolism in CHD patients [122]. However, their study
did not evaluate protein metabolism in the period following the
termination of dialysis when an increase in amino acid flux was
demonstrated in normal subjects [121].
The effect of hemodialysis membranes on nutritional aspects of
CHD patients was further supported clinically in studies by
Lindsay and colleagues [123]. These investigators established a
link between PCR, a putative marker of DPI in stable CHD
patients, with the modality and the dose of dialysis. They further
suggested that at a given dialysis dose, patients dialyzed with a
biocompatible dialysis membrane had a higher PCR compared to
patients dialyzed with a bioincompatible membrane.
The mechanism by which the biocompatibility and activation of
the complement pathway enhances protein catabolism is not clear.
Production of cytokines, such as interleukin-1 and tumor necrosis
factor-alpha (TNF-a) may induce muscle protein degradation and
excess amino acid release [124, 125]. In studies by Gutierrez et al
[1201, the release of amino acids during dialysis with bioincom-
patible membranes was most prominent at six hours after the
initiation of hemodialysis, a time period consistent with activation
of monocytes and subsequent release of cytokines, followed by
their action on muscle cells [126]. Complement activation has
been shown to result in increased transcription of TNF-a and in a
recent study by Canivet and co-workers increased serum TNF-a
concentrations were reported in CHD patients dialyzed with a
complement activating membrane [127].
One of the most important factors that affects the nutritional
status of dialysis patients is the dose of dialysis. The results of the
NCDS, where an association between lower protein intake and
higher time-averaged urea concentrations was observed, sug-
gested a relationship between underdialysis and anorexia [451.
More recently, Lindsay et al have hypothesized that PCR was
dependent on the type and the dose of dialysis [128]. Bergstrom
and Lindhom have also reported a significant linear relationship
between Kt/V and PCR, all consistent with anorexia related to
underdialysis [129]. However, these retrospective and/or cross-
sectional studies did not definitively show a cause and effect
relationship between dose of dialysis and nutrition. Furthermore,
whether the decreased PCR really reflects the nutritional status of
these patients has become the subject of debate that has not been
resolved. It has been suggested that the relationship between dose
of dialysis, as measured by Kt/V and PCR, is actually a mathe-
matical artifact, and not a metabolic response reflecting better
nutrition. In this respect, in a recent large cross-sectional study by
Owen et al, no statistically significant relationship between serum
albumin and dose of dialysis was seen [6]. Nevertheless, it is quite
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clear that decreasing clearance of uremic substances is associated
with progressive anorexia at all stages of renal failure.
Factors related to peritoneal dialysis
Similar observations have been made in PD patients with
regard to factors that predispose these patients to malnutrition.
Lindsay et a! have hypothesized the same association between
dose of dialysis and dietary protein intake in CAPD patients [123].
Bergstrom and Lindholm have also reported similar findings with
regard to their dialysis patients, with the additional observation
that CAPD patients required a lower dialysis dose as compared to
HD patients to achieve a given dietary protein intake [129]. They
have postulated that better removal of middle molecules which
are thought to be the causal factor in the anorexia associated with
uremia is the explanation for this relationship.
An important report on this issue is the cross-sectional analysis
of an international study on the nutritional status of CAPD
patients. In this study, a higher incidence of malnutrition was
observed in patients who were treated with CAPD for longer than
three months compared to patients who were treated less than
three months, suggesting that as residual renal function decreases
(a major contributor to total clearance in PD patients) indices of
malnutrition become more evident [130]. Keshaviah et a! have
also suggested that as residual renal function declines in CAPD
patients, PCR also decreases [131]. Teehan et a! and Lameire et
a! reported higher survival rates and better nutritional markers
with higher Kt/V [132, 133]. Although several etiological factors
have been postulated, it is not yet well-established by which
mechanisms underdialysis causes decreased protein and calorie
intake.
Losses of proteins and amino acids into the dialysate fluid have
long been identified as a catabolic factor in PD patients. Several
studies have reported a loss of 5.5 to 11.8 grams of proteins into
the dialysate daily [134]. A large amount of these losses consists of
albumin, along with immunoglobulins as well as amino acids. Free
amino acid losses have been estimated to be in the range of 1.7 to
3.4 g per day according to different studies [135]. Most impor-
tantly, during episodes of peritonitis, these losses of proteins and
amino acids increase substantially [1341. The generally lower
serum albumin concentrations, as well as several abnormalities in
plasma amino acid profiles seen in PD patients is presumed to be
a result of these inevitable losses.
Conversely, the amount of energy intake, at least indirectly, is
relatively higher in PD patients, due to the absorption of glucose
from the dialysate fluid. This absorption usually provides energy
in the range of 5 to 20 kcal/kg daily in many patients and is
possibly the explanation for the relatively lower resting energy
expenditure levels observed in this patient population [136].
Unfortunately, this absorption of glucose may also predispose
these patients to further anorexia due to the development of
satiety, in addition to the feeling of fullness related to the fluid in
the peritoneal cavity. The extensive presence of protein malnutri-
tion in these patients, in spite of this increased energy consump-
tion, is probably related to their inadequate intake of dietary
protein since protein intake affects nitrogen balance more pro-
foundly than the overall energy intake 11371.
In addition to above mentioned factors, hormonal and meta-
bolic derangements observed during pre-dialysis stage may persist
or even worsen during the renal replacement stage of ESRD,
irrespective of the modality of dialysis. Furthermore, placement of
permanent or temporary vascular accesses in CHD patients and
use of the peritoneal cavity in PD patients induce additional
medical problems and hospitalizations due to infections and/or
access revisions, Increased frequency of hospitalizations may
adversely affect the nutritional status of dialysis patients [138].
Indeed, a recent preliminary report by our laboratory has sug-
gested that the actual daily protein intake of CHD patients
admitted to a regular ward is at perilously low levels (0.55 0.33
g/kg/day) and that simultaneous calculations of PCR by urea
kinetics revealed a negative nitrogen balance in 80% of these
hospitalized patients [48]. Serum albumin concentrations showed
a significant decrease with hospitalizations in these patients.
Therefore, frequent hospital admissions may also be an insidious
and important cause of poor nutrition in chronic dialysis patients.
Factors related to renal transplantation
Although renal transplantation probably offers the best nutri-
tional rehabilitation at present, it is still associated with some
degree of malnutrition. The most probable cause for this subop-
timal nutritional status is chronic and at times high use of
corticosteroids. It is well-known that corticosteroids are associ-
ated with increased net protein catabolism and decreasing visceral
protein concentrations [139, 1401. Studies by Miller et al and
Horber et al have identified corticosteroid associated abnormali-
ties in anthropometrics, as well as abnormalities in skeletal muscle
ultrastructure in renal transplant patients [63, 64]. Hoy et a! also
reported that increases in corticosteroid dosage further increased
PCR [1411.
Another issue related to renal transplant patients is utilization
of low-protein diets to alter the course of rejection. Although
several uncontrolled and short-term studies suggested some pre-
liminary immunological benefit on rejection, in a relatively well-
designed study, significant decreases in almost all serum proteins,
including serum total protein, albumin, prealbumin, and trans-
ferrin were observed with a diet consisting of 0.5 g/kg/day
low-protein in renal transplant patients with chronic rejection,
while no significant changes occurred in GFR [142, 143]. The
results of another small scale study actually suggested beneficial
effects of a high protein diet with regard to side effects of
corticosteroids [144]. Whether other factors, such as frequency of
acute rejections, number of infectious complications, and other
immunosuppressive agents play any role on the overall nutritional
picture of the transplant patient remains to be determined.
In summary, it is evident that there are multiple factors that
predispose ESRD patients to malnutrition. Although some of
these factors, such as anorexia, and hormonal and metabolic
abnormalities, are encountered at all stages of ESRD, some are
specific to the type of the modality of RRT.
Prevention and treatment of malnutrition in ESRD patients
Predialysis patients
A list of measures to prevent and/or to treat malnutrition in
different stages of ESRD is presented in Table 2. The above-
mentioned hormonal and metabolic derangements, such as insulin
resistance and amino acid abnormalities, are usually inevitable in
patients with progressive renal failure. However, other factors
that adversely affect the nutritional status of CRF patients, such as
the extent of anorexia, may be altered. In light of the evidence
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Table 2. Interventions to prevent and/or treat malnutrition
(1) Pre-dialysis patients
-Optimal dietary protein and calorie intake
-Optimal timing for initiation of dialysis, before onset of indices
of malnutrition
(2) Dialysis patients
-Appropriate amount of dietary protein intake (> 1.2 g/kg/day)
along with nutritional counseling to encourage increased intake
-Optimal dose of dialysis (Kt/V > 1.4 or URR > 65%)
-Use of biocompatible dialysis membranes
-Enteral or intradialytic parenteral nutritional supplements
(hemodialysis) and amino acid dialysate (peritoneal dialysis) if
oral intake is not sufficient
-Growth factors (experimental):
-Recombinant human growth hormone
-Recombinant human insulin-like growth factor-I
(3) Transplant patients:
-Appropriate amount of dietary protein intake
-Avoidance of excessive use of immunosuppressives
-Early reinitiation of dialytic therapy with proper steroid tapering
in patients with chronic rejection
suggesting that decreasing spontaneous dietary protein and en-
ergy intake is a prominent feature of decreasing renal function
and correlates with worsening nutritional indices, it is obvious that
any dietary intervention designed to limit dietary intake during
the pre-dialysis stage must be undertaken cautiously. Patients on
restricted diets should be followed very closely for signs and
symptoms of malnutrition and necessary adjustments must be
made if malnutrition is suspected. In particular, patients on
dietary protein restriction should have provision for adequate
calorie intake.
For the majority of patients who are not on a closely monitored
dietary protein restriction, evident signs of poor nutrition, such as
spontaneous DPI less than 0.75 g!kg/day and energy intake less
than 20 kcal/kg/day, serum albumin concentrations < 4.0 g/dI,
apparent decrements in other nutritional indices, such as trans-
ferrin, prealbumin, IGF-1, and lean body mass, may warrant
initiation of RRT [71. Several studies have indeed suggested
better outcomes with early initiation of RRT. Specifically, the
length of hospital stay, the mortality within the first 90 days after
initiation of dialysis, as well as the long-term mortality were all
better in patients who were initiated on dialysis early in their
course of renal failure compared to patients who were referred to
RRT rather late [47, 1451. It is possible that early initiation of
RRT prevents the development of malnutrition and its related
complications and improves long-term outcome. These comments
should not be taken to imply that a high protein intake should be
encouraged in patients with chronic renal failure; rather, we
suggest that a low protein and energy intake in patients on
spontaneous (unrestricted) diets, dietary protein intake of less
than 0.75 g/kg/day is an early warning sign for the development of
malnutrition.
Dialysis patients
An algorithm of assessment of the nutritional status and dietary
interventions in chronic dialysis patients is shown in Figure 1.
These interventions will be discussed in detail below.
Dose of dialysis. The previously mentioned studies have high-
lighted the association between underdialysis and poor nutrition
in chronic dialysis patients. Therefore, it is evident that an
adequate dose of dialysis is required to prevent development of
malnutrition in these patients. Lindsay and co-workers prospec-
tively analyzed the effects of increasing the dialysis dose in a group
of patients with PCR values <1 g/kg/day [146]. Their results
showed that PCR increased significantly in the group of patients
whose Kt/V values were increased, whereas there was no change
in PCR values in the group of patients whose Kt/V values
remained the same. In studies by Burrowes et al and Acchiardo et
al, significant increases in serum albumin concentrations were
demonstrated in chronic HD patients when their dose of dialysis
was increased to adequate levels [147—149]. Most recently, Hakim
et al have performed a prospective four years study where the
dose of dialysis was increased intentionally to 1.33 (measured by
delivered Kt/V) in 130 CHD patients [150]. They observed that
the standardized mortality rates of the patients declined from
22.8% to 9.1% and when the nutritional parameters of patients
with yearly average double-pool Kt!V values below 0.86 and above
1.21 were identified, statistically significant differences were found
between serum albumin, transferrin and PCR measurements.
With regard to the adequacy of CAPD, similar conclusions can
be derived from several retrospective studies which show signifi-
cant correlations between dialysis dose and nutritional parameters
[151]. Most recently, results from a large scale multicenter
prospective study were published and have suggested a positive
relationship between adequacy of dialysis and nutritional status in
CAPD patients [152].
All the available evidence in ESRD patients therefore confirm
the close association between dialysis dose and nutrition. It is
important to note, however, that the specific level of optimal dose
of dialysis, after which no further improvement in nutritional
status is observed has not been established yet. Several prospec-
tive studies are underway to evaluate this question.
Dialysis membrane. Several experimental and cross-sectional
studies have highlighted the catabolic and anorectic effects of
bioincompatible membranes [120, 146]. However, it is still not
clearly established whether long-term use of hiocompatible mem-
branes per se can improve the nutritional markers in CHD
patients. In fact, the first evidence that supports the argument that
biocompatible hemodialysis membranes favorably impact on the
nutritional status of CHD patients was recently reported by our
laboratory [391. In a prospective randomized study of 159 new
hemodialysis patients randomized to either a low-flux biocompat-
ible membrane or a low-flux bioincompatible membrane, we
measured the effects of biocompatibility on several nutritional
parameters, including estimated dry weight, serum albumin, and
IGF-1 over 18 months. Our results showed that the biocompatihie
group had a mean increase in their dry weight of 4.36 8.57 kg
at the end of the study, whereas no change in mean weight was
observed in the bioincompatible group. In addition, the hiocom-
patible group had an earlier (6 months vs. 12 months) and more
marked increase in serum albumin concentrations compared to
the bioincompatible group, as well as consistently higher IGF-l
values. In fact, recent reports from the USRDS have suggested
that use of hioincompatible membranes are associated with
increased risk of death in comparison to biocompatible mem-
branes [153]. Whether altered nutritional status plays a role in this
process is not clear. However, a recent analysis of cause of death
in these two groups of patients dialyzed with biocompatible versus
bioincompatible membranes highlighted the significant increase
of infection related deaths in the bioiricompatihle group [154]. It
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— Continuous decrease in EDW
— Serum albumin <4.0 g/dl
— PCR < 1.0 g/kg/day
Visceral proteins
Detailed Prealbumin <30 mgldl
assessment Transferrin <200 mg/dl
IGF-1 <200 ng/ml
Dietary supplementation:
A) Food supplements
B) P0 amino acids
C) Enteric tube feeding
Reassess nutritional
markers in 2—3 months
1) Intradialytic parenteral nutrition
(with medicare approval)
2) Growth factors (experimental)
rhGH
rhlGF-1
Fig. 1. A schematic diagram of assessment of the
nutritional status and dietary interventions in end-
s/age renal disease patients. Abbreviations are:
EDW, estimated dry weight; PCR, protein
catabolic rate; IGF-1, insulin-like growth factor
I; BIA, bioelectrical impedance analysis; RRT,
renal replacement therapy; CRF, chronic renal
failure; rhGH, recombinant human growth
hormone; rhlGF-1, recombinant human insulin-
like growth factor 1.
is possible that poor nutritional status may increase the preva-
lence of infectious episodes in patients dialyzed with bioincom-
patible membranes and eventually increase the risk of death.
Nevertheless, further studies are required to evaluate the cause
and effect relationship between these factors.
Nutritional intake. Considering the catabolic nature associated
with chronic dialysis, it is clear that attempts to encourage patients
to maintain an adequate protein and calorie intake must be
provided to chronic dialysis patients. It is a common experience
that most of these patients continue their pre-dialysis diets while
on chronic RRT. It is the nephrologists' responsibility to ensure
that the dietary protein and calorie intake of these patients fulfill
the increased requirements after initiation of dialysis. Repetitive
comprehensive dietary counseling by an experienced dietitian is
an important step to improve dietary intake, as well as detection
of early signs of malnutrition. Similar efforts should be spent not
only in outpatient settings, but also during hospitalizations of
these patients. These hospitalized patients should be closely
followed by experienced renal dietitians during their frequent and
at times long hospital admissions, since as mentioned above these
patients have even lower dietary protein and calorie intake.
Enteral and intradialytic parenteral nutrition. Aggressive dietary
counseling to improve nutritional status unfortunately is usually
unsuccessful in optimizing the dietary intake in most of the
malnourished dialysis patients [1551. For these patients other
forms of supplementation such as enteral (including oral protein,
amino acid tablets and energy supplementation [156—1581, naso-
gastric tubes [90], percutaneous endoscopic gastroscopy or jeju-
nostomy tubes [159]) and intradialytic parenteral nutrition
(IDPN)) are suggested. Only a limited number of studies evalu-
ating the effects of enteral supplementation in malnourished
ESRD patients are available [157, 158, 160, 161]. Furthermore,
most of these studies are not controlled and are small in scope and
the degree of success is variable. Therefore, for the nephrologist
Brief
assessment
Suspected
malnutrition
Somatic proteins
Inappropriately low
pre-dialysis creatinine
Decrease in lean body mass:
Anthropometrics; BIA
Dietary counseling to increase dietary:
— Protein intake (1.2 g/kg/day)
— Calorie intake (30—35 kcal/day)
Increase dialysis dose to KtN >1.4
Use biocompatible membranes
Upper Gl motility enhancers
Timely initiation of RRT in CRF patients
Reassess nutritional
markers in 2—3 months
Simple
interventions
Moderate
interventions
Complex
interventions
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Table 3. Studies using growth factors as anabolic agents in ESRD patients
Study Agent Dose Patients Duration Outcome Complications
Ziegler et al [1751 rhGH 5—10 mg/day 5 (HD) 3 weeks . UN generation None
Schulman et al [381 rhGH 5 mg q HD
+ IDPN
7 (HD) 6 weeks I Sai',; .j. PCR None
Ikizier et al [1761 rhGH 5 mg/day 10 (PD) 7 days UN, P04, K
serum creatinine
Hyperglycemia in
1 diabetic patient
Ikizier et al [1351 rhGH 5 mg/day 10 (PD) 7 days . plasma essential AA Hyperglycemia in
Kang et al [177] rhGH 10 U/m2 tiw 10 (PD) 12 weeks . UN generation
1' lean body mass
1 diabetic patient
None
Kopple [1821 rhGH 50 rg/kg/day 5 (HO) 17 days Improvement in NB
Less response in 2 patients
with acute illnesses
None
Peng et al [178] rhIGF-1 50—100 jzg/kg bid 6 (PD) 20 days Improved NB
No change in S1
and anthropometrics
None
Abbreviations are: rhGH, recombinant human growth hormone; HD, hemodialysis; UN, urea nitrogen; Slb, serum albumin; PCR, protein catabolic
rate; PD, peritoneal dialysis; IDPN, intradialytic parenteral nutrition; P04, serum phosphorus; K, serum potassium; AA, amino acids; NB, nitrogen
balance; rhIGF-1, recombinant human insulin-like growth factor-i.
it is usually a challenge to determine whether an enteral form of
supplementation is effective or not and when to try further
relatively expensive measures such as IDPN.
Several recent reports have emphasized the effective use of
IDPN as a potential therapeutic intervention in malnourished
chronic dialysis patients [162]. This mode of treatment has been
advocated after a trial of enteral nutritional supplementation. The
early studies by Heidland and Kult, as well as several subsequent
studies, reported positive effects of intradialytic infusions of
nutrients on several nutritional parameters [13, 163]. In contrast,
several other studies were not able to show any benefit of IDPN
[164, 165]. Importantly, all these studies had drawbacks in their
designs and patient populations, and therefore no definitive
conclusions could be made. In a more recent study, Cano et al
reported improvements in multiple nutritional parameters with
IDPN in a group of 26 malnourished CHD patients [166]. In a
retrospective analysis of more than 1,500 CHD patients treated
with IDPN, Chertow et al have reported decreasing risk of death
with the use of IDPN, particularly in patients with serum albumin
concentrations below 3.5 g/dl and serum creatinine concentrations
below 8 mg/dl [167]. They were able to show substantial improve-
ments in these parameters following use of IDPN. These findings
suggested that this mode of treatment is probably most useful in
patients with moderate to severe malnutrition.
Studies using amino acid dialysate (AAD) in CAPD patients
have also provided conflicting results. In studies which suggested
benefit from AAD, serum transferrin and total protein concen-
trations increased and plasma amino acid profiles tended towards
normal with I or 2 exchanges of AAD [168, 1691. On the other
hand, an increase in BUN concentrations associated with exacer-
bation of uremic symptoms as well as metabolic acidosis noted to
be complications of AAD [168—170]. Kopple et al reported
significant short-term improvements in nitrogen balance studies,
as well as serum total protein and transferrin concentrations in 19
malnourished CAPD patients treated with AAD [171]. In a more
recent study, in abstract form, Jones et al reported significant
improvements in serum albumin and prealbumin concentrations
in malnourished CAPD patients particularly in those who had
serum albumin concentrations within the lowest tertile [172].
These results are consistent with the reports in CHD patients
suggesting that these interventions are probably most useful in
patients with severe malnutrition.
In summary, the available evidence suggests that IDPN and
AAD may be useful in the treatment of malnourished chronic
dialysis patients and offers an alternative method of nutritional
intervention in a group of dialysis patients in whom oral or enteral
intake cannot be maintained. However, most of the studies
evaluating IDPN are retrospective, uncontrolled and short-term.
Furthermore, there are no clear data to prove that aggressive
nutritional supplementation through the gastrointestinal tract is
actually inferior to parenteral supplementation in dialysis pa-
tients. Until a controlled study comparing various forms of
nutritional supplementation in similar patient groups is com-
pleted, one should be cautious in choosing highly costly nutri-
tional interventions; thus, there is an urgent need to initiate
prospective studies to evaluate the long-term effects of IDPN and
compare it to different forms of enteral nutrition.
Growth factors. As previously mentioned, growth hormone and
its major mediator IGF-1 have several anabolic properties. With
the availability of recombinant forms of these agents, recombinant
human growth hormone (rhGH) has been utilized in multiple
patient populations at pharmacological doses to promote net
anabolism [100]. Consequently, with the recognition of alterations
in growth hormone-IGF-1 axis in ESRD patients, rhGH has been
proposed as a potential anabolic agent in this patient population
[173] (Table 3). Several animal studies have suggested that rhGH
induces a net anabolic action in uremic rats and also improves
food utilization [174]. Furthermore, a preliminary short-term
study in CHD patients by Ziegler et al demonstrated a decrease of
pre-dialysis BUN concentrations by approximately 25% and a
significant reduction in net urea generation and PCR with rhGH
administration [175]. In a subsequent study by our laboratory
where rhGH was given to seven malnourished MD patients in
association with IDPN, the combination of IDPN with rhGH
resulted in significant improvements in serum albumin, transferrin
and IGF-1 concentrations [38].
Similar net anabolic actions of rhGH have also been observed
in CAPD patients. In a controlled prospective study by Ikizier et
al, rhGH treatment was shown to induce a substantial (29%)
decrease in net urea generation in 10 CAPD patients [176].
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Interestingly, these changes were associated with concurrent
statistically significant decreases in serum potassium and phos-
phorus concentrations, as well as an increase in serum creatinine
concentrations, suggestive of a net anabolic process in muscle
mass. In a subsequent analysis of amino acid (AA) profiles of the
same patients, the net anabolic processes induced by rhGH
reflected a shift in AA metabolism towards peripheral muscle
tissues [135]. Several other studies in abstract form also suggested
consistent results with rhGH administration in CAPD patients
[177].
Since IGF-1 is the major mediator of growth hormone action,
recombinant human IGF-1 has also been proposed as an anabolic
agent. Preliminary nitrogen balance studies in CAPD patients are
consistent with this hypothesis, however the side effect profile of
this agent, at least as observed in CRF patients, may impede its
wide spread use at this time [1781. Interestingly, the combined
utilization of these agents in healthy subjects seems to provide the
most efficient anabolic action with the least side effect profile
[179]. It is yet unknown whether the long term use of these agents
in malnourished CHD and CAPD patients would result in im-
proved nutritional parameter and hence in better outcome. Nev-
ertheless, such studies should be encouraged in these patient
populations.
Transplant patients
As is the case with other aspects of nutrition in transplant
patients, the prevention and/or the treatment of malnutrition in
these patients have not been studied in detail. However, one can
propose that such interventions should include avoiding unneces-
sary or excessive use of catabolic agents, particularly in patients
with frequent acute rejection episodes in their early transplant
stages. For patients with chronic rejections, it is crucial not to
delay the initiation of RRT as well as provision of an efficient
tapering of corticosteroid dosages. It is a common experience that
most transplant patients who are initiated on RRT are still on
chronic corticosteroid therapy, which for most patients is unnec-
essary.
It is clear that much work is needed in this patient population
with regard to nutrition. Therefore, studies that evaluate the
importance of nutrition in transplant patients with acute and
chronic rejection should be encouraged. Finally, the importance
and efficacy of rhGH in pediatric uremic and transplant patients
have been highlighted by several studies [180, 181].
Summary
In summary, it is evident that malnutrition is highly prevalent in
ESRD patients. This is clearly related to multiple factors encoun-
tered during the pre-dialysis stage, as well as during maintenance
dialysis therapy. A body of evidence highlights the existence of
relationship between malnutrition and outcome in this patient
population. Several preliminary studies suggest that interventions
to improve the poor nutritional status of the ESRD patients may
actually improve the expected outcome in these patients, although
their long-term efficacy is not well established. It is therefore
important to emphasize that malnutrition is a major co-morbid
condition in the ESRD population and that the nutritional status
and the treatment parameters of these patients should be altered
to improve not only the mortality outcome of ESRD patients but
also their quality of life.
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